Reference health
A phase <scp>II</scp>, single‐arm, multicentre study of coltuximab ravtansine (<scp>SAR</scp>3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma
19/19 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
7 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 19 checked references that resolve
resolves10.1200/JCO.2009.25.1900
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
resolves10.1023/A:1008416911099
Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma
resolves10.1158/1078-0432.CCR-11-0485
SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
resolves10.1111/j.1472-8206.2009.00714.x
Pharmacokinetics of rituximab associated with CHOP chemotherapy in B‐cell non‐Hodgkin lymphoma
resolves10.1200/JCO.2010.29.5865
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
resolves10.1177/107327481201900305
Diffuse Large B-Cell Lymphoma: Current Strategies and Future Directions
resolves10.1200/JCO.2010.28.1618
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
resolves10.1007/s00277-015-2467-z
Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment
resolves10.1182/blood-2014-09-598763
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
resolves10.1007/s11899-013-0169-y
The Impact of MYC Rearrangements and “Double Hit” Abnormalities in Diffuse Large B-Cell Lymphoma
resolves10.1200/jco.2014.32.15_suppl.8519
Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).
resolves10.3324/haematol.2013.090597
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial
resolves10.1182/blood-2011-09-380949
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
resolves10.1158/1078-0432.CCR-13-0580
A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
resolves10.1200/JCO.2014.60.2383
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
resolves10.1200/JCO.2011.39.4403
Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
The 7 references without a DOI — listed, not checked
no DOI — not checkedInterim analysis of a phase 1, open‐label, dose‐escalation study of SGN‐CD19A in patients with relapsed or refractory B‐lineage non‐Hodgkin lymphoma (NHL)
no DOI — not checkedPhase I/II study of MEDI‐551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B‐cell malignancies
no DOI — not checkedPhase I and pharmacokinetic study of ABI‐007, a Cremophor‐free, protein‐stabilized, nanoparticle formulation of paclitaxel
no DOI — not checkedA success story: how a single targeted‐therapy molecule impacted on treatment and outcome of diffuse large B‐cell lymphoma
no DOI — not checkedTargeting CD19 in B‐cell lymphoma: emerging role of SAR3419
no DOI — not checkedSTARLYTE: phase II study of coltuximab ravtansine (SAR3419) single agent: clinical activity and safety in patients with relapsed/refractory diffuse large B‐cell lymphoma (NCT01472887)
no DOI — not checkedTreatment of relapsed/refractory diffuse large B‐cell lymphoma with the bispecific T‐cell engager (TiTE) antibody construct blinatumomab: primary analysis results from an open‐label, Phase 2 study
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1111/bjh.13992"><img src="https://citestamp.com/citestamped/10.1111/bjh.13992/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1111/bjh.13992)